文献速递神经免疫

儿童复发型髓鞘少突胶质细胞糖蛋白抗体相关疾病的病程与治疗反应

Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
PubMed 文献 · JAMA Neurol · 2018-01-01

该研究前瞻性收集了来自8个国家EU儿童脱髓鞘疾病联盟的102例复发型MOG抗体相关疾病患儿(2014年1月1日至2016年12月31日),中位年龄7.0岁。结果显示,干扰素β和醋酸格拉替雷治疗前后中位ARR和EDSS评分无变化;硫唑嘌呤、吗替麦考酚酯、利妥昔单抗可降低ARR但EDSS评分不变;定期静脉注射免疫球蛋白可改善ARR和EDSS评分。作者认为DMDs与临床改善无关,而硫唑嘌呤、吗替麦考酚酯、利妥昔单抗、特别是静脉注射免疫球蛋白与复发频率降低相关。

要点

  • 干扰素β和醋酸格拉替雷治疗前后中位ARR和EDSS评分无变化(n=11)。
  • 硫唑嘌呤(n=20)、吗替麦考酚酯(n=15)、利妥昔单抗(n=9)可降低中位ARR但EDSS评分不变。
  • 定期静脉注射免疫球蛋白(n=12)可改善ARR(从2.16降至0.51)和EDSS评分(从2.2降至1.2)。

核心结论

  • DMDs虽常用于治疗多发性硬化患者,但在MOG抗体相关疾病患儿中未与临床改善相关。
  • 硫唑嘌呤、吗替麦考酚酯、利妥昔单抗、特别是静脉注射免疫球蛋白与复发频率降低相关。
  • 正确诊断复发型MOG抗体相关疾病对于优化免疫治疗很重要。

研究设计与样本

  • 该研究为前瞻性收集人口学、临床和影像学数据的研究,纳入来自8个国家EU儿童脱髓鞘疾病联盟的102例患者,收集时间为2014年1月1日至2016年12月31日,患者按当地方案治疗。

主要发现

  • 共识别102例儿童,中位年龄7.0岁(范围1.5-7.9),男女比1.0:1.8,白人与其他种族/族裔比3.6:1.0。
  • 原诊断分别为视神经脊髓炎谱系疾病44例(43.1%)、急性播散性脑脊髓炎后视神经炎20例(19.6%)、多相性播散性脑脊髓炎20例(19.6%)、复发性视神经炎18例(17.6%)。
  • 共报告464次脱髓鞘事件;治疗患者复发次数(中位3.0次,范围1.0-17.0)多于未治疗患者(中位1.0次,范围1.0-7.0)(P=.009),EDSS评分(中位1.5,四分位距0-2.5)高于未治疗患者(中位1.0,四分位距0-1.5)(P<.001)。
  • 52例儿童(51.0%)接受DMDs:28例(53.8%)接受1种DMD,17例(32.7%)接受2种,7例(13.5%)接受3种或以上序贯DMDs;所有治疗期间均有复发,共报告127次治疗中复发。
  • 干扰素β和醋酸格拉替雷治疗前后中位ARR和EDSS评分无变化(n=11);硫唑嘌呤中位ARR从1.84降至1.0(n=20,P<.001),吗替麦考酚酯从1.79降至0.52(n=15,P=.003),利妥昔单抗从2.12降至0.67(n=9,P<.001),但中位EDSS评分均保持不变;12例定期静脉注射免疫球蛋白患者ARR改善(从2.16降至0.51,P<.001)且EDSS评分改善(从2.2降至1.2,P=.01)。

关键数值与推荐

  • 硫唑嘌呤治疗n=20,中位ARR从1.84降至1.0(P<.001)。
  • 吗替麦考酚酯治疗n=15,中位ARR从1.79降至0.52(P=.003)。
  • 利妥昔单抗治疗n=9,中位ARR从2.12降至0.67(P<.001)。
  • 定期静脉注射免疫球蛋白治疗n=12,ARR从2.16降至0.51(P<.001),EDSS评分从2.2降至1.2(P=.01)。
  • 干扰素β和醋酸格拉替雷治疗n=11,治疗前后中位ARR和EDSS评分无变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) are consistently identified in a range of demyelinating disorders in adults and children. Current therapeutic strategies are largely center specific, and no treatments have been formally evaluated. OBJECTIVE: To examine the clinical phenotypes, treatment responses, and outcomes of children with relapsing MOG-Ab-associated disease. DESIGN, SETTING, AND PARTICIPANTS: This study prospectively collected demographic, clinical, and radiologic data from 102 patients from 8 countries of the EU Paediatric Demyelinating Disease Consortium from January 1, 2014, through December 31, 2016. Patients were treated according to local protocols. MAIN OUTCOMES AND MEASURES: Annualized relapse rates (ARRs) and Expanded Disability Status Scale (EDSS) scores before and during treatment with disease-modifying drugs (DMDs). RESULTS: A total of 102 children were identified (median [range] age, 7.0 [1.5-7.9] years; male to female ratio, 1.0:1.8; white to other race/ethnicity ratio, 3.6:1.0). Original diagnoses were neuromyelitis optica spectrum disorder (44 patients [43.1%]), acute disseminated encephalomyelitis followed by optic neuritis (20 [19.6%]), multiphasic disseminated encephalomyelitis (20 [19.6%]), and relapsing optic neuritis (18 [17.6%]). In all, 464 demyelinating events were reported. Treated patients had more relapses (median, 3.0; range, 1.0-17.0) than untreated patients (median, 1.0; range 1.0-7.0) (P = .009) and higher EDSS scores (median, 1.5; interquartile range, 0-2.5) than untreated patients (median, 1.0; interquartile range, 0-1.5) (P < .001). Fifty-two children (51.0%) received DMDs: 28 (53.8%) were treated with 1 DMD, 17 (32.7%) with 2, and 7 (13.5%) with 3 or more sequential DMDs. Patients relapsed during all treatments, with a total of 127 relapses on treatment reported. No changes in median ARR and EDSS score were observed between the preinitiation and postinitiation phases of interferon beta and glatiramer acetate treatment (n = 11). The median ARR was reduced from 1.84 to 1.0 with azathioprine (n = 20, P < .001), 1.79 to 0.52 with mycophenolate mofetil (n = 15, P = .003), and 2.12 to 0.67 with rituximab (n = 9, P < .001), although the median EDSS score remained unchanged. An improvement in ARR (from 2.16 to 0.51, P < .001) and EDSS score (from 2.2 to 1.2, P = .01) was observed in the 12 patients treated with regular intravenous immunoglobulins. CONCLUSIONS AND RELEVANCE: Although commonly used to treat patients with multiple sclerosis, DMDs were not associated with clinical improvement in children with MOG-Ab-associated disease, whereas azathioprine, mycophenolate mofetil, rituximab, and particularly intravenous immunoglobulins were associated with a reduction in relapse frequency. A correct diagnosis of relapsing MOG-Ab-associated disorders is therefore important to optimize immune treatment.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hacohen Y, Wong YY, Lechner C, et al. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2018. PMID: 29305608. doi:10.1001/jamaneurol.2017.4601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。